Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 193

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer

Halabi, Susan, Vogelzang, Nicholas J., Kornblith, Alice B., Ou, San-San, Kantoff, Philip W., Dawson, Nancy A., Small, Eric J. · 2008 · Journal of Clinical Oncology

Abstract

Purpose: Pain from castration-refractory prostate cancer (CRPC) bone metastases is a common event. Although it is assumed that pain represents an adverse prognostic factor, this variable has not been extensively evaluated. The objective of this study was to determine whether men with CRPC who had higher pain interference scores at baseline had worse clinical outcomes compared with men who had lower pain scores. Patients and Methods: Data from three randomized phase III multicenter trials conducted by the Cancer and Leukemia Group B from 1992 to 1998 were combined. Eligible patients had progressive CRPC adenocarcinoma of the prostate, an Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate hematologic, renal, and hepatic functions. Seven items from the Brief Pain Inventory were used to assess the impact of pain on a range of daily activities and quality of life, each rated on a scale from 0 to 10. Results: In 599 men, the median pain interference scores was 17 (interquartile range, 4 to 34), and 38% of the men had opioid analgesic use at baseline. There was a statistically significant association between pain interference scores and risk of death. The median survival times were 17.6 months (95% CI, 16.1 to 19.1 months) and 10.2 months (95% CI, 8.6 to 11.3 months; P < .001) in men with low (< 17) and high (≥ 17) pain scores, respectively. Pain was inversely associated with likelihood of prostate-specific antigen decline, objective response, and time to bone progression. Conclusion: This analysis demonstrates that pain is a statistically significant predictor of overall survival in men with metastatic CRPC. These results need to be validated prospectively in future phase III trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.15.0367

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 193

Metadata

Authors
Halabi, S., Vogelzang, N. J., Kornblith, A. B., Ou, S.-S., Kantoff, P. W., Dawson, N. A., & Small, E. J.
Venue
Journal of Clinical Oncology
Published
2008-05-20
Volume
26
Issue
15
Pages
2544-2549
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2142200772
Cited by
193
References
2
FWCI
11.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.2007.15.0367
The paper
Halabi, S., Vogelzang, N. J., Kornblith, A. B., Ou, S.-S., Kantoff, P. W., Dawson, N. A., & Small, E. J. (2008). Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.0367

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.